1. A possible role of miRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. (April 2016) Authors: Liese, J.; Peveling-Oberhag, J.; Doering, C.; Schnitzbauer, A.A.; Zangos, S.; Hansmann, M.L.; Moench, C.; Welker, M.W.; Zeuzem, S.; Bechstein, W.O.; Ulrich, F. Journal: HPB Issue: Volume 18(2016)Supplement 2 Page Start: e834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acoustic radiation force impulse imaging for non‐invasive assessment of liver fibrosis in chronic hepatitis B. Issue 4 (31st July 2012) Authors: Friedrich‐Rust, M.; Buggisch, P.; de Knegt, R. J.; Dries, V.; Shi, Y.; Matschenz, K.; Schneider, M. D.; Herrmann, E.; Petersen, J.; Schulze, F.; Zeuzem, S.; Sarrazin, C. Journal: Journal of viral hepatitis Issue: Volume 20:Issue 4(2013) Page Start: 240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Commentary: vitamin D deficiency and liver cancer – cause, effect or myth? Authors' reply. Issue 12 (June 2014) Authors: Finkelmeier, F.; Kronenberger, B.; Köberle, V.; Bojunga, J.; Zeuzem, S.; Trojan, J.; Piiper, A.; Waidmann, O. Journal: Alimentary pharmacology & therapeutics Issue: Volume 39:Issue 12(2014) Page Start: 1429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Issue 5 (May 2023) Authors: Mahmoudi, S.; Bernatz, S.; Ackermann, J.; Koch, V.; Dos Santos, D.P.; Grünewald, L.D.; Yel, I.; Martin, S.S.; Scholtz, J.-E.; Stehle, A.; Walter, D.; Zeuzem, S.; Wild, P.J.; Vogl, T.J.; Kinzler, M.N. Journal: Clinical oncology Issue: Volume 35:Issue 5(2023) Page Start: e312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Issue 4 (14th February 2013) Authors: Foster, G. R.; Zeuzem, S.; Pianko, S.; Sarin, S. K.; Piratvisuth, T.; Shah, S.; Andreone, P.; Sood, A.; Chuang, W.‐L.; Lee, C.‐M.; George, J.; Gould, M.; Flisiak, R.; Jacobson, I. M.; Komolmit, P.; Thongsawat, S.; Tanwandee, T.; Rasenack, J.; Sola, R.; Messina, I. Journal: Journal of viral hepatitis Issue: Volume 20:Issue 4(2013) Page Start: e115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low‐to‐moderate genetic barrier nucleoside analogs. Issue 4 (15th November 2012) Authors: Peveling‐Oberhag, J.; Herrmann, E.; Kronenberger, B.; Farnik, H.; Susser, S.; Sarrazin, C.; Zeuzem, S.; Hofmann, W.‐P. Journal: Journal of viral hepatitis Issue: Volume 20:Issue 4(2013) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Editorial: HBsAg serum levels in HBeAg‐negative chronic HBV infection—is it a matter of genotype? Authors' reply. Issue 1 (7th June 2018) Authors: Kuhnhenn, L.; Jiang, B.; Kubesch, A.; Zeuzem, S.; Sarrazin, C.; Hildt, E.; Peiffer, K.‐H. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 1(2018) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection. Issue 11 (10th April 2018) Authors: Kuhnhenn, L.; Jiang, B.; Kubesch, A.; Vermehren, J.; Knop, V.; Susser, S.; Dietz, J.; Carra, G.; Finkelmeier, F.; Grammatikos, G.; Zeuzem, S.; Sarrazin, C.; Hildt, E.; Peiffer, K.‐H. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 11(2018) Page Start: 1523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. Issue 1 (21st June 2013) Authors: Mihm, U.; Welker, M.‐W.; Teuber, G.; Wedemeyer, H.; Berg, T.; Sarrazin, C.; Böhm, S.; Alshuth, U.; Herrmann, E.; Zeuzem, S. Journal: Journal of viral hepatitis Issue: Volume 21:Issue 1(2014) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Inhibition of the oncoprotein FUBP1 by SN-38 represents a novel therapeutic option for the treatment of hepatocellular carcinoma. (December 2016) Authors: Hauck, S.; Khageh Hosseini, S.; Wesely, J.; Trojan, J.; Gerlach, K.; Schulze, J.; Hahn, S.; Steinhilber, D.; Gatterdam, V.; Zeuzem, S.; Waidmann, O.; Zangos, S.; Biondi, R.; Proschak, E.; Zörnig, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗